Topiramate in migraine prophylaxis: Data from a pooled analysis and open-label extension study

G. Bussone, S. Usai, D. D'Amico

Research output: Contribution to journalArticlepeer-review

Abstract

Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.

Original languageEnglish
JournalNeurological Sciences
Volume27
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2006

Keywords

  • Clinical trial
  • Migraine
  • Open-label extension phase
  • Pooled analysis
  • Prophylaxis
  • Topiramate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Topiramate in migraine prophylaxis: Data from a pooled analysis and open-label extension study'. Together they form a unique fingerprint.

Cite this